US Patent Issued to REGENERON PHARMACEUTICALS on April 21 for "Antagonist anti-NPR1 antibodies and methods of use thereof" (New Jersey, New York Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,618, issued on April 21, was assigned to REGENERON PHARMACEUTICALS INC. (Tarrytown, N.Y.).

"Antagonist anti-NPR1 antibodies and methods of use thereof" was invented by Michael E. Dunn (Montvale, N.J.) and Lori C. Morton (Chappaqua, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the disclosure, the antibodies are fully human antagonist antibodies that bind to NPR1. In some embodiments, the antibodies of the disclosure are useful for blocking NPR1 signaling and/or activity, th...